Endocrine Abstracts

Objectives: Graves’ hyperthyroidism is a frequent complication of alemtuzumab treatment in MS. We present the case of an MS patient who developed clinically and biochemically overt alemtuzumab-induced Graves’ disease, remitting 6 months after treatment with ocrelizumab and methylprednisolone pulse-therapy.Methods: A 49-year-old man diagnosed with active multiple sclerosis who had undergone alemtuzumab treatment, and developed Graves’ hyper...

Objectives: A role of IgG4 in Graves’ disease (GD) has been proposed, although the available data are conflicting. In addition, an association between Graves’ orbitopathy (GO) and IgG4-related disease has been postulated, but no firm demonstration has been obtained. Thus, the aim of the present study was to investigate the role of IgG4 in GD.Methods: We performed a cross-sectional investigation in 351 consecutive patients (F=284, M=67; age 48.2...

Introduction: Several studies identified pre-treatment parameters that could help in the prediction of the thyroid functional outcome after radioactive iodine therapy (RAI) in Graves’ disease. However, the role of the thyroid peroxidase antibody (TPO Ab) status is not well studied.Objectives: We investigated if a positive TPO Ab status before radioactive iodine (RAI) therapy in patients with Graves’ hyperthyroidism is a predictive factor for de...

Objective: Graves’ Disease (GD) is one of the most common autoimmune disorders. Some SNP in pro-inflammatory cytokines have already been linked to an increased susceptibility of developing GD. Thyroid hormones are crucial modulators of lipid metabolism. A pro-inflammatory state, may contribute several metabolic changes, including disturbances in lipid metabolism. Our aim was to evaluate if SNP in pro-inflammatory cytokines also contribute to disturbances of lipid profile ...

Objective: We aim of the study was to investigate the clinical approach to Graves’ disease (GD) treatment among endocrinologists in Russia.Materials and methods: An online questionnaire survey was conducted among doctors from Sept till Dec 2021. The questions covered the principles of diagnosis, treatment and dynamic observation of adults with GD.Results: 104 endocrinologists participated in the study. 99% of respondents chose...

Aims: Surgery is the only curative treatment for medullary thyroid cancer (MTC) patients and the gold standard practice is still represented by total thyroidectomy and prophylactic central neck compartment lymphnode dissection. As it happened for differentiated thyroid cancer, in the last years some authors proposed less aggressive and extent surgical modality as hemithyroidectomy and ipsilateral neck compartment dissection in unilateral and solitary sporadic MTC cases. Few st...

Objective: An enhancement of the response rate has been recently showed in patients with Graves’ ophthalmopathy (GO) treated with corticosteroids and mycophenolic acid. In GO, retro-orbital cells showed a cytokine-induced secretion of Th1 and Th2 chemokines. Since no data are present in literature about the effect of corticosteroids and mycophenolic acid on the chemokines secretion in GO orbital cells, we aim to deepen out this topic.Methods: We est...

Objectives: Glucocorticoids (GCs) are the first line therapy in moderate to severe, active thyroid eye disease (TED). While their beneficial immunosuppressive effects are well known, direct connective tissue effects are less characterized. The accumulation of extracellular matrix component hyaluronan (HA) and increased proliferation rate of fibroblasts are hallmarks connective tissue changes in TED. We examined the effect of methylprednisolone (MP), prednisolone (P), hydrocort...

Objectives: Overt hyperthyroidism is reported to be associated with an increased mortality risk and an increased risk of cardiovascular (CV) complications such as an acute coronary syndrome requiring percutaneous coronary intervention, ischemic and non-ischemic stroke, atrial fibrillation and venous thromboembolism. Increased rate of acute CV events in the course of hyperthyroidism is well documented in Graves’ disease (GD) but not in subacute thyroiditis (ST). Last year ...

Introduction: Thyrotropin receptor stimulating antibodies (TRAb) are responsible for Graves’ disease (GD) manifestations. Other thyroid antibodies, namely thyroperoxidase (TPOAb) and thyroglobulin (TGAb) antibodies are highly prevalent in GD, but their roles in GD presentation and evolution are controversial.Methods: We retrospectively analysed TPOAb and TGAb levels and evolution in 88 consecutive patients with newly diagnosed GD between 2000 and 20...